№ lp_1_35690
File format: docx Character count: 30056 File size: 88 KB
A submission to the Australian PBAC for the listing of tenofovir alafenamide (TAF) as a treatment for chronic hepatitis B (CHB), comparing its efficacy and safety with tenofovir disoproxil fumarate (TDF) and entecavir.
Year: 2017
Region / city: Australia
Subject: Chronic Hepatitis B, Antiviral Therapy
Document Type: Submission for PBS listing
Agency / institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: GILEAD SCIENCES
Target audience: Healthcare professionals, policymakers
Period of validity: Not specified
Approval date: 22 February 2017
Amendment date: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Clinical Commissioning Policy Tenofovir alafenamide for treatment of HIV 1 in adults and adolescents
Year: 2025
Region / City: England
Theme: HIV Treatment, Antiretroviral Therapy
Document Type: Policy Statement
Organization / Institution: NHS England
Author: NHS England
Target Audience: Healthcare professionals, policy makers
Effective Period: Ongoing from May 2025
Approval Date: May 2025
Date of Last Update: August 2025
Clinical Commissioning Policy for Tenofovir Alafenamide in the Treatment of HIV-1 in Adults and Adolescents
Year: 2021
Region: England
Subject: HIV-1 treatment
Document type: Clinical commissioning policy
Organization: NHS England
Target audience: Adults and adolescents living with HIV-1
Approved date: 2021
Drug reviewed: Tenofovir alafenamide (TAF)
Treatment context: Antiretroviral therapy (ART)
Purpose: Funding and clinical guidance for TAF use
Evidence reviewed: Comparative safety and efficacy versus TDF
Population: Patients with contraindications to TDF or with complications during treatment
Topics: VEMLIDY GILEAD alafenamide